Encapsulation of Plant-Derived Cycloheptapeptide Mallotumide A in Riboflavin-Modified Poly(Lactic-Co-Glycolic Acid)/Chitosan Nanoparticles
Issued Date
2026-01-01
Resource Type
ISSN
14387492
eISSN
14392054
Scopus ID
2-s2.0-105028087061
Journal Title
Macromolecular Materials and Engineering
Volume
311
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Macromolecular Materials and Engineering Vol.311 No.1 (2026)
Suggested Citation
Manohong P., Sawektreeratana N., Nuchpun S., Kumkoon T., Payomhom P., Laowittawat C., Jitrapakdee S., Lee H.M., Reutrakul V., Kuhakarn C., Katewongsa K.P. Encapsulation of Plant-Derived Cycloheptapeptide Mallotumide A in Riboflavin-Modified Poly(Lactic-Co-Glycolic Acid)/Chitosan Nanoparticles. Macromolecular Materials and Engineering Vol.311 No.1 (2026). doi:10.1002/mame.202500385 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/114519
Title
Encapsulation of Plant-Derived Cycloheptapeptide Mallotumide A in Riboflavin-Modified Poly(Lactic-Co-Glycolic Acid)/Chitosan Nanoparticles
Corresponding Author(s)
Other Contributor(s)
Abstract
Mallotumide A (MA) is a novel cycloheptapeptide isolated from the roots of Mallotus spodocarpus Airy Shaw. It exerts anticancer activity by downregulating several lipogenic enzymes and cellular respiration, particularly in triple-negative breast cancer. However, MA has poor water solubility and is highly toxic to both cancer and normal cells, limiting its therapeutic applications. To address these drawbacks, MA was encapsulated within poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) and coated with riboflavin (Rf)-modified chitosan (CR), creating (MA)PLGA/CR NPs. This study characterized the NPs and investigated their encapsulation efficiency of MA, cellular uptake, and anticancer activity in two breast cancer (MDA-MB-231 and MCF-7) and normal (MCF-10A) cell lines. The NPs were spherical with an average size of 300 ± 6.64 nm and a zeta potential of +11.96 mV. The PLGA/CR NPs exhibited enhanced cellular uptake in both cancer cells in a dose- and time-dependent manner, while reducing toxicity in normal cells. Furthermore, the (MA)PLGA/CR NPs inhibited the viability, migration, and invasion of MDA-MB-231 cells, thereby demonstrating their potential as a targeted anticancer delivery system.